COMPARISON OF ARGON PLASMA COAGULATION AND FORMALIN INSTILLATION IN THE TREATMENT OF RADIATION INDUCED HAEMORRHAGIC PROCTOCOLITIS
Abstract
Background: Radiotherapy is routinely used in the treatment of pelvic malignancies and about 2–5% of these patients develop radiation-induced proctitis or proctocolitis. This complication of radiotherapy is treated in different ways. Two of these treatments, argon plasma coagulation (APC) and formalin instillation, have both been reported as to be successful modalities, but data comparing them are scarce. We conducted this study to compare these two treatment options.
Methods: We reviewed the charts of patients who had radiation-induced proctocolitis and who were treated endoscopically at our tertiary care cancer centre with either APC or formalin instillation. Outcomes of the two treatments were compared in terms of bleeding control after the first session of treatment, the number of sessions required and the nal response to therapy.
Results: Out of a total of 26 patients presenting with haemorrhagic radiation proctocolitis, 11 were treated with APC and 15 with formalin instillation. Success after the rst session was 53% in the formalin instillation group compared to 18% in the APC-treated group. On repeated sessions, the final response to both treatment modalities was comparable.
Conclusion: Efficacy of APC and formalin instillation in the treatment of haemorrhagic radiation proctocolitis is comparable although formalin showed a better outcome after the first session.
Key words: Argon plasma coagulation, formalin instillation, proctitis, radiation-induced colitis
References
Moore EM, Magrino TJ, Johnstone PA. Rectal bleeding after radiation therapy for prostate cancer: Endoscopic evaluation. Radiology 2000;217:215-8.
Melko GP, Turco TF, Phelan TF, et al. Treatment of radiation induced proctitis with sucralfate enemas. Ann Pharmacother 1999;33:1274-6.
Chun M, Kang S, Kil HJ, et al. Rectal bleeding and its management after irradiation for uterine cervical cancer. Int J Radiat Oncol Biol Phys 2004;58:98-105.
Gul YA, Prasannan S, Jabar FM, et al. Pharmacotherapy for chronic hemorrhagic radiation proctitis. World J Surg 2002;26: 1499-502.
Ventrucci M, Di Simone MP, Giulietti P, et al. Ef cacy and safety of Nd: YAG laser for the treatment of bleeding from radiation proctocolitis. Dig Liver Dis 2001;33:230-3.
Sebastian S, O’Connor H, O’Morain C, et al. Argon plasma coagulation as rst-line treatment for chronic radiation proctopathy. J Gastroenterol Hepatol 2004;19:1169-73.
Rubinstein E, Ibsen T, Rasmussen RB, et al. Formalin treatment of radiation-induced hemorrhagic proctitis. Am J Gastroenterol 1986;81:44-5.
Baum CA, Biddle WL, Miner PB Jr. Failure of 5-aminosalicylic acid enemas to improve chronic radiation proctitis. Dig Dis Sci 1989;34:758-60.
Woo TC, Joseph D, Oxer H. Hyperbaric oxygen treatment for radiation proctitis. Int J Radiat Oncol Biol Phys 1997;38: 619-22.
FarinG,GrundKE.Technologyofargonplasmacoagulation with particular regard to endoscopic applications. Endosc Surg Allied Technol 1994;2:71-7.
Tjandra JJ, Sengupta S. Argon plasma coagulation is an effective treatment for refractory hemorrhagic radiation proctitis. Dis Colon Rectum 2001;44:1759-65.
Tagkalidis PP, Tjandra JJ. Chronic radiation proctitis. ANZ J Surg 2001;71:230-7.
Canard JM, Védrenne B, Bors G, et al. Long term results of treatment of hemorrhagic radiation proctitis by argon plasma coagulation. Gastroenterol Clin Biol 2003;27:455-9.
MathaiV,Seow-ChoenF.Endoluminalformalintherapyfor haemorrhagic radiation proctitis. Br J Surg 1995;82:190.
Alfadhli AA, Alazmi WM, Ponich T, et al. Ef cacy of argon plasma coagulation compared to topical formalin application for chronic radiation proctopathy. Can J Gastroenterol 2008;22:129 32.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.
